May 23, 2026 — RNews

#copd — Saturday, May 23, 2026 (1 items)

hot top new

← prev day next day →

0

Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials. (linkinghub.elsevier.com)

Papi A … Brightling CE The Lancet 2026-05-23

#antibody #inflammation #immunotherapy #copd #exacerbation